Lantheus Holdings, Inc., a Delaware corporation, entered into a definitive agreement with PharmaLogic Holdings Corp. to sell its contract development and…
Lantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 8, 2026, Lantheus Holdings, Inc., a Delaware corporation (“Lantheus” or the “Company”), entered into a definitive agreement with PharmaLogic Holdings Corp. (“PharmaLogic”) to sell its contract development and manufacturing organization (“CDMO”)
How this was made
The 30-second read
Why it matters
The transaction removes a non‑core asset, likely reducing revenue but providing cash and a supply partnership, creating short‑term downside risk.
Market read
Primary corporate action that could move LNTH shares; sector peers may be indirectly affected.
What to watch
Potential tax benefits and strategic focus on core radiopharmaceuticals could offset revenue loss.
Background
Lantheus Holdings (LNTH) filed an 8‑K reporting the sale of its contract development and manufacturing organization (CDMO) and a New Jersey plant to PharmaLogic, along with a long‑term supply agreement for lutetium Lu‑177 dotatate.
Ticker impact
Lantheus disclosed a definitive agreement to sell its CDMO business and a New Jersey facility to PharmaLogic, a material corporate divestiture.
likely pressure as the market prices in reduced revenue and integration risk
Divestitures typically trigger share declines unless offset by cash proceeds; the transaction is pending closing and carries execution risk.
Market effects
May signal consolidation in the CDMO space, affecting peers like Catalent and Lonza.
Limited to U.S. biotech manufacturing sector.
Modest; primarily impacts Lantheus and its immediate competitors.
Counterpoint
If the sale price is sizable and cash is used for high‑growth initiatives, the stock could rebound.
Key entities
- CompanyLantheus Holdings, Inc.
Seller of CDMO business, ticker LNTH.
- CompanyPharmaLogic Holdings Corp.
Buyer of the CDMO business.
